BioSpace News Archive

Disc Medicine, Inc. announced the pricing of its upsized underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced the pricing of its underwritten public offering of 7,575,000 shares of its common stock at a price to the public of $29.75 per share.

Sensei Biotherapeutics, Inc. announced that the Company will host a virtual KOL event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors,” on Tuesday, June 27, 2023 at 2:00 p.m.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma solution developed by its subsidiary, BioStrand®.

W. L. Gore & Associates announced the initiation of the Gore VBX FORWARD Clinical Study to compare the VBX Stent Graft to bare metal stenting for patients with complex iliac occlusive disease.

DAMONA Pharmaceuticals announced the appointment of John Reilly as the company’s Chief Executive Officer and member of the Board of Directors.

NeuroBo Pharmaceuticals, Inc. announced that data on DA-1726, a novel oxyntomodulin analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, was accepted for one ePoster theater discussion and two general poster presentations at the American Diabetes Association 83rd Scientific Sessions, being held June 23-26, 2023 at the San Diego Convention Center in San Diego, CA and virtually.

Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial evaluating the safety and efficacy of the Bare Temporary Spur Stent System.

MEI Pharma, Inc. announced that, consistent with the Company’s succession planning, Brian Drazba’s tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin File as his successor.

Applied StemCell, Inc. and the California Institute for Regenerative Medicine have partnered as Industry Resource Partners.